APT 3111

Drug Profile

APT 3111

Alternative Names: APT 2392; CD59-Prodaptin

Latest Information Update: 02 Aug 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Inflazyme Pharmaceuticals
  • Class
  • Mechanism of Action CD59 antigen agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Paroxysmal nocturnal haemoglobinuria

Highest Development Phases

  • Discontinued Paroxysmal nocturnal haemoglobinuria

Most Recent Events

  • 30 Apr 2005 Discontinued - Preclinical for Paroxysmal nocturnal haemoglobinuria in United Kingdom (unspecified route)
  • 21 Apr 2004 Adprotech has been acquired by Inflazyme Pharmaceuticals
  • 19 May 2003 APT 3111 has received orphan drug status for paroxysmal nocturnal haemoglobinuria in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top